A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease

Ophthalmology. 2021 Aug;128(8):1125-1128. doi: 10.1016/j.ophtha.2021.03.006. Epub 2021 Apr 3.

Authors

Richard C Allen¹, Elizabeth A Bradley², Robert G Fante³, Mark J Lucarelli⁴

Affiliations

¹ Houston, Texas. Electronic address: richardcutlerallen@gmail.com.
² Rochester, Minnesota.
³ Aurora, Colorado.
⁴ Madison, Wisconsin.

PMID: 33823982
DOI: 10.1016/j.ophtha.2021.03.006

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / economics
Antibodies, Monoclonal, Humanized / therapeutic use*
Autoimmune Diseases / drug therapy*
Drug Approval
Drug Costs
Graves Ophthalmopathy / drug therapy*
Humans
Immunotherapy / adverse effects
Immunotherapy / economics
Immunotherapy / methods*
Receptor, IGF Type 1 / immunology*
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal, Humanized
Receptor, IGF Type 1
teprotumumab